Epigenetic Involvement in Etiopathogenesis and Implications in Treatment of Systemic Lupus Erythematous

Overview

Journal Inflamm Res

Specialties Allergy & Immunology
Pathology

Date 2017 Jul 26

PMID 28741130

Citations 8

Authors

Arron Munggela Foma

Saeed Aslani

Jafar Karami

Ahmadreza Jamshidi

Mahdi Mahmoudi

Affiliations

Soon will be listed here.

Abstract

Background: Recent researches in the field of genetics have extended our knowledge through the discovery of genetic factors associated with autoimmune diseases (AID). Genetics by itself, however, cannot elucidate all the uncertainties encountered in the etiopathology of AID. On the other hand, incomplete harmony in the prevalence of AID in identical twins suggests that non-genetic factors may play an important role in determining the disease susceptibility. Besides, epigenetics, which is defined by changes in gene expression without a corresponding change in the DNA sequences, has come in to provide new awareness in the disease etiopathology by bridging the genetic and epigenetic factors. The recent advances in the field of epigenetics provide a new insight into the understanding of the disease mechanisms, development, diagnostic and prognostic approaches, as well as the various treatment methods.

Purpose: This review paper aims to present an overview of epigenetic modifications involved in the pathogenesis of systemic lupus erythematosus (SLE) and discuss their important roles in clinical and pharmacological settings, including novel and recent therapeutic applications.

Results: Nowadays, it is believed that autoimmune diseases, such as SLE, begin when genetically susceptible factors associate with environmental triggers. The current therapeutic approaches for SLE treatment have been based on treatments with immunosuppressive drugs, which are linked to various side effects. It is difficult to develop highly effective treatments for SLE patients with minimal or no side effects, mainly due to the disease complexity. The breakthrough of pharmacoepigenetics provides a new approach to solve this problem. Epigenetic modifications can influence the efficacy of drugs by changing the gene expression through modifying chromatin remodeling. In this regard, epigenetic studies in SLE are expected to reveal novel disease biomarkers and therapeutic targets.

Conclusions: Accumulating evidence disclosed that epigenetic dysregulations are engaged in SLE pathogenesis and may be exerted as biomarkers to diagnose and as tools to treat these patients.

Citing Articles

Dysregulated MicroRNAs in the Pathogenesis of Systemic Lupus Erythematosus: A Comprehensive Review.

Choi D, Kim J, Yang J, Kim J, Park S, Shin J Int J Biol Sci. 2023; 19(8):2495-2514.

PMID: 37215992 PMC: 10197884. DOI: 10.7150/ijbs.74315.

The Epigenetic Contribution to the Pathogenesis of Psoriasis: Recent Advances.

Aslani S, Mirarefin S, Zarredar H, Asadi M, Javan M, Khosrojerdi A Curr Med Chem. 2023; 31(29):4621-4639.

PMID: 37138420 DOI: 10.2174/0929867330666230503143824.

Association of interleukin 33 gene polymorphisms with susceptibility and regulation of inflammatory mediators in Systemic lupus erythematosus patients.

Bagheri-Hosseinabadi Z, Mirzaei M, Aliakbari M, Abbasifard M Clin Rheumatol. 2023; 42(8):2187-2197.

PMID: 37067648 DOI: 10.1007/s10067-023-06575-y.

Evaluation of CX3CR1 gene DNA methylation in developmental dysplasia of the hip (DDH).

Nejadhosseinian M, Haerian H, Shirkoohi R, Karami J, Mortazavi S J Orthop Surg Res. 2022; 17(1):436.

PMID: 36175906 PMC: 9523927. DOI: 10.1186/s13018-022-03324-w.

Association study between KIR polymorphisms and rheumatoid arthritis disease: an updated meta-analysis.

Aghaei H, Mostafaei S, Aslani S, Jamshidi A, Mahmoudi M BMC Med Genet. 2019; 20(1):24.

PMID: 30696403 PMC: 6352331. DOI: 10.1186/s12881-019-0754-6.

References

Wang H, Peng W, Ouyang X, Li W, Dai Y . Circulating microRNAs as candidate biomarkers in patients with systemic lupus erythematosus. Transl Res. 2012; 160(3):198-206. DOI: 10.1016/j.trsl.2012.04.002. View

Hu N, Qiu X, Luo Y, Yuan J, Li Y, Lei W . Abnormal histone modification patterns in lupus CD4+ T cells. J Rheumatol. 2008; 35(5):804-10. View

Scaria V, Hariharan M, Maiti S, Pillai B, Brahmachari S . Host-virus interaction: a new role for microRNAs. Retrovirology. 2006; 3:68. PMC: 1626483. DOI: 10.1186/1742-4690-3-68. View

Grabiec A, Korchynskyi O, Tak P, Reedquist K . Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay. Ann Rheum Dis. 2011; 71(3):424-31. PMC: 3277722. DOI: 10.1136/ard.2011.154211. View

Helin K, Dhanak D . Chromatin proteins and modifications as drug targets. Nature. 2013; 502(7472):480-8. DOI: 10.1038/nature12751. View

Pan Y, Zhang Y, Jia T, Zhang K, Li J, Wang L . Development of a microRNA delivery system based on bacteriophage MS2 virus-like particles. FEBS J. 2012; 279(7):1198-208. DOI: 10.1111/j.1742-4658.2012.08512.x. View

Ullal A, Reich 3rd C, Clowse M, Criscione-Schreiber L, Tochacek M, Monestier M . Microparticles as antigenic targets of antibodies to DNA and nucleosomes in systemic lupus erythematosus. J Autoimmun. 2011; 36(3-4):173-80. DOI: 10.1016/j.jaut.2011.02.001. View

Zhang H, Xiao W, Hou P . [Clinical study of total glucosides of paeony in patients with systemic lupus erythematosus]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2011; 31(4):476-9. View

Tahmasebi Z, Akbarian M, Mirkazemi S, Shahlaee A, Alizadeh Z, Amirzargar A . Interleukin-1 gene cluster and IL-1 receptor polymorphisms in Iranian patients with systemic lupus erythematosus. Rheumatol Int. 2013; 33(10):2591-6. DOI: 10.1007/s00296-013-2784-2. View

10.

Cornacchia E, Golbus J, Maybaum J, Strahler J, Hanash S, Richardson B . Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J Immunol. 1988; 140(7):2197-200. View

11.

Danchenko N, Satia J, Anthony M . Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus. 2006; 15(5):308-18. DOI: 10.1191/0961203306lu2305xx. View

12.

Garaud S, Le Dantec C, Jousse-Joulin S, Hanrotel-Saliou C, Saraux A, Mageed R . IL-6 modulates CD5 expression in B cells from patients with lupus by regulating DNA methylation. J Immunol. 2009; 182(9):5623-32. DOI: 10.4049/jimmunol.0802412. View

13.

Pradeep Velagapudi S, Gallo S, Disney M . Sequence-based design of bioactive small molecules that target precursor microRNAs. Nat Chem Biol. 2014; 10(4):291-7. PMC: 3962094. DOI: 10.1038/nchembio.1452. View

14.

Carlsen A, Schetter A, Nielsen C, Lood C, Knudsen S, Voss A . Circulating microRNA expression profiles associated with systemic lupus erythematosus. Arthritis Rheum. 2013; 65(5):1324-34. PMC: 6662589. DOI: 10.1002/art.37890. View

15.

Pan Y, Sawalha A . Epigenetic regulation and the pathogenesis of systemic lupus erythematosus. Transl Res. 2008; 153(1):4-10. DOI: 10.1016/j.trsl.2008.10.007. View

16.

Qin H, Zhu X, Liang J, Yang Y, Wang S, Shi W . Associations between aberrant DNA methylation and transcript levels of DNMT1 and MBD2 in CD4+T cells from patients with systemic lupus erythematosus. Australas J Dermatol. 2012; 54(2):90-5. DOI: 10.1111/j.1440-0960.2012.00968.x. View

17.

Taganov K, Boldin M, Chang K, Baltimore D . NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A. 2006; 103(33):12481-6. PMC: 1567904. DOI: 10.1073/pnas.0605298103. View

18.

Lin S, Hsieh S, Lin Y, Lee C, Tsai M, Lai L . A whole genome methylation analysis of systemic lupus erythematosus: hypomethylation of the IL10 and IL1R2 promoters is associated with disease activity. Genes Immun. 2011; 13(3):214-20. DOI: 10.1038/gene.2011.74. View

19.

Munro S, Mitchell M, Ponnampalam A . Histone deacetylase inhibition by trichostatin A mitigates LPS induced TNFα and IL-10 production in human placental explants. Placenta. 2013; 34(7):567-73. DOI: 10.1016/j.placenta.2013.04.004. View

20.

Zhao M, Liu S, Luo S, Wu H, Tang M, Cheng W . DNA methylation and mRNA and microRNA expression of SLE CD4+ T cells correlate with disease phenotype. J Autoimmun. 2014; 54:127-36. DOI: 10.1016/j.jaut.2014.07.002. View